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Introduction 
 
Fabry disease, or Anderson-Fabry disease, was first described in 1898 by two separate 
physicians, William Anderson (London) and Johannes Fabry (Germany)1,2. They 
independently described patients with 'angiokeratoma corporis diffusum', the now well 
recognized characteristic dermatological manifestations of this condition. It is perhaps 
more commonly known as Fabry disease since Johannes Fabry suggested a systemic 
disorder was responsible. We now know that Fabry disease is a multi-system 
progressive X-linked lysosomal storage disorder due to alpha-galactosidase deficiency, 
which can present in numerous ways to different clinicians3,4. As a result the diagnosis 
is often delayed for many years or even decades5.  
 
Fabry disease is often only clinically recognised in the classical form of the disorder, 
associated with undetectable alpha-galactosidase activity, resulting in impaired 
degradation of neutral glycosphingolipids, particularly globotriaosylceramide (GL-3)5. 
Progressive accumulation of these substances in various tissues and body fluids 
produces end organ damage, which subsequently leads to presentations with 
neurological, dermatological, renal, cardiac or cerebrovascular signs or symptoms, in 
combination or isolation, from the first decade of life onwards.  
 
Average age of symptom onset in males is 9 years and 13 years for females yet the age 
of diagnosis is 23 and 32 years respectively. Life expectancy is reduced by 17 years in 
affected males and by 6 years in affected females. It is now recognised that the ‘classical’ 
form of the disease represents only one end of a spectrum associated with impaired 
glycosphingolipids metabolism. At the other end of the spectrum are asymptomatic 
females, whilst in between exist variant forms of the disease in affected males and 
females. Variant forms of the disease are associated with detectable but low enzyme 
levels, with isolated renal and cardiac forms described. The variation in disease 
manifestations, over time and between different organs, helps to explain the delay in 
achieving a diagnosis.  
 
Making the correct diagnosis avoids harm from unnecessary procedures and 
investigations undertaken to evaluate symptoms but most importantly allows 
consideration of enzyme replacement therapy (ERT). ERT has been shown to stablilise 
progression of the disease, but having only been in existence since 2001, no mortality 
benefit has been demonstrated to date. As yet there is no international agreement on 
ERT but there is a consensus view (Mehta et al). Given the difficulties in reaching the 
correct diagnosis in a timely fashion, the wide presentation of disease and the questions 
remaining regarding ERT, it is clear that a greater understanding of this complex multi-
system single gene disorder is desirable. 
 
We have identified a family where three affected brothers (X, Y & Z) have markedly 
different variants of Fabry disease yet unusually share an identical gene mutation. Such 
wide phenotypic variation within siblings, or varied phenotype-genotype correlation, 
has not previously been reported and offers the opportunity to enhance our 
understanding of the disease.  
 
This report also demonstrates the heterogeneity of Fabry disease presentations and 
phenotypes, whilst serving as a reminder to all physicians, whether general or 
specialised, of the value of exploring family histories, even after several years. It also 
highlights that Fabry disease is not such a rare disorder when one considers both 
classical and variant forms, since the true number of variant forms is unknown but 
more common than previously reported6. 
 
Identifying Familial Disease 
 
A routine clinic review of patient X, known to our department for over 30 years, with a 
cadaveric renal transplant and presumed hypertensive renal failure, identified an 
unusual family history, where both surviving brothers were under investigations by 
cardiologists for non-ischaemic heart disease. Patient X, the eldest of 3 brothers, had 
presented to our department in 1975, aged 25 with severe hypertension, requiring 
dialysis in 1978 and then received a cadaveric kidney transplant in 1980. 
  
Separately, younger brothers Y & Z had been investigated for a variety of symptoms 
over several years. Cardiological assessment of sibling Y had revealed unexplained 
severe left ventricular hypertrophy, refractory to anti-hypertensive therapy, prompting 
consideration of other diagnoses. His cardiologist referred the patient for a tertiary 
centre cardiac assessment with a view to possible cardiac biopsy. However no 
additional investigations were performed at that time. 
 
Confirming Familial Disease 
 
As both renal and cardiac clinicians became aware of the emerging family history and 
entered into correspondence, Fabry disease was considered. Blood spot or serum alpha-
galactosidase levels were assessed using standard techniques (Figure 1A) and showed 
alpha-galactosidase deficiency (but importantly not absence of enzyme activity). 
Classical Fabry disease is associated with undetectable enzyme levels, whereas atypical 
or variant disease is associated with low enzyme levels3, suggesting our siblings had a 
variant form of the disease. Pedigree analysis revealed an inherited disorder compatible 
with X-linked disease (Figure 1B). The elder male sibling had died from cancer in his 
fifth decade and we are therefore unaware of his status. 
 
Genetic mutation analysis of the entire alpha-galactosidase gene revealed that all 3 
siblings shared an identical missense mutation (Figure 1C). The base pair mutation 
identified, R301Q in exon 6, results in the substitution of arginine with glutamine 
(Figure 1C). This mutation was first described in 19907 and, although it results in 
targeted early degradation of an aberrantly folded alpha-galactosidase enzyme, is 
associated with a degree of residual enzymatic activity3 – in keeping with the serum 
enzyme assay results obtained in this family (Figure 1A) and previous observations in 
variant forms of the disease3. 
 
Phenotypic Characterisation 
 
With the molecular genetic diagnosis confirmed, we sought to characterise disease 
manifestations in each sibling, summarised in Table 1. Initial assessment clinically 
suggested that sibling X had a renal variant of Fabry disease whereas siblings Y and Z 
had a cardiac variant. Both cardiac7 and renal8 variants of Fabry disease have been 
described in patients carrying the R301Q mutation but no reports exist of both variants 
within the same family.  
 
Renal disease involvement 
 
Fabry disease affects the kidney via the accumulation and deposition of uncleaved 
neutral glycosphingolipids in various essential specialised cells (podocytes, endothelial, 
mesangial and interstitial cells). This results in several abnormalities of renal function 
but typically in microalbuminuria and proteinuria, which worsens with age, ultimately 
progressing to end stage disease9.  
 
Sibling X originally had a native renal biopsy performed in 1975 but in our centre it is 
routine practice for samples to be discarded after 30 years, hence original biopsy 
samples were not available for retrospective analysis. However samples were available 
from bilateral native nephrectomies performed in 1984 for severe hypertension, four 
years post-cadaveric renal transplantation, when patient X was age 34. 
 
Analysis was limited, as the specimens were not processed for diagnostic assessment at 
that time. Examination of haematoxylin and eosin (H&E) stained sections revealed 
features of end stage renal disease (Figure 2A) only but electron microscopy images 
revealed a myelin figure or zebra body in keeping with a diagnosis of renal Fabry 
disease (Figure 2B). These appearances represent deposits of glycosphingolipids within 
enlarged secondary lysosomes as lamellated membrane structures, composed of 
concentric layers with a periodicity of 3.5 to 5 nm and with an onion skin appearance10.  
 
Thus, sibling X had renal disease that progressed to end-stage requiring renal 
replacement therapy, initially in the form of dialysis and subsequently renal 
transplantation. His renal transplant is still functioning well 32 years post-
transplantation, in keeping with renal Fabry disease, as a donor kidney should have 
normal alpha-galactosidase levels. Ultra structural changes in keeping with Fabry 
disease have been reported in donor kidneys, possibly via migration of recipient 
endothelial cells, but not in sufficient amounts for recurrent disease to be evident or 
change graft function11.  
 
Despite the early severe renal disease in sibling X, both siblings Y and Z appear to have 
normal renal function when most recently assessed by serum creatinine (Table 1). In 
addition, given that serum creatinine is a poor marker of early renal dysfunction, 
neither sibling Y or Z have significant proteinuria. The lack of renal involvement for 
these siblings provides a stark phenotypic contrast to their older sibling sharing the 
same genotype.  
 
Cardiac disease involvement 
 
Cardiac involvement in Fabry disease includes left ventricular hypertrophy (LVH), 
arrhythmia, angina and dyspnoea in approximately 40-60% of patients12. Together 
renal and cardiac disease account for the reduction in life expectancy observed in Fabry 
disease; which is approximately 17 years for males and 5 years for females13. Over time, 
cardiac disease has increasingly accounted for the mortality observed, as patients with 
renal failure survive longer on renal replacement therapy in the form of dialysis and 
transplantation13. 
 
Typically LVH is concentric and progressive myocardial fibrosis is seen, with 
replacement fibrosis typically seen in the posterior-lateral wall and mid-
myocardium3,12. Cardiac MRI performed when siblings X, Y & Z were 61, 59, & 51 years 
old respectively, showed these characteristic findings, with more severe cardiac disease 
in siblings Y & Z, despite younger age and much shorter duration of hypertension 
(Figure 3A & B). As described earlier, sibling Y had been successfully treated for 
hypertension for 1 year, yet without any appreciable change in LVH and guidance 
suggests that patients with unexplained or atypical LVH should be tested for Fabry 
disease14. 
 
Malignant arrhythmias account for a significant proportion of cardiac deaths in Fabry 
disease15. Sibling Z is under consideration for ICD implantation for resistant ventricular 
dysrhythmias, as he has not responded to treatments offered thus far, despite ERT. 
Neither sibling X or Y appear to have had symptomatic arrhythmias. The differences in 
hypertrophy observed do not explain the resistant arrhythmias seen in sibling Z. It 
should be remembered that the images portray a cross-section of the sibling’s 
myocardium only (Figure 3A & B). Coronary angiography in siblings Y and Z 
demonstrated normal coronaries, whilst full analyses of the MRI images show more 
extensive myocardial infiltration in sibling Z (data not shown) despite similar degrees of 
LVH. This tends to support the hypothesis that ventricular arrhythmias are related to 
fibrotic scars rather than LV hypertrophy or systolic dysfunction alone15. 
 
These images also show that patient X does not have a renal limited variant. A Japanese 
study examining screening dialysis patients for Fabry disease showed that six of 514 
patients had previously undiagnosed variant forms of Fabry disease16. Of these 6 
patients, 5 had LVH and all had missense mutations other than the R301Q mutation 
with low alpha-galactosidase levels15. Thus sibling X appears to have a recognised 
variant form with predominant renal involvement and cardiac disease also. 
 
Other systems involvement and Enzyme replacement therapy 
 
Clinical assessment of these siblings to date suggests that in addition to renal and 
cardiac involvement, there appear to be some neurological manifestations but no other 
features of Fabry disease (Table 1). Acroparathesia has been the predominant form of 
neurological involvement, with MRI brain analysis not suggestive of Fabry disease (data 
not shown). These siblings seem to have variant disease involving 3 systems to differing 
degrees of severity.  
 
ERT appears to be a safe and effective therapy if initiated early enough, with the ability 
to stabilise disease in other organ systems, even for those requiring dialysis for 
example17. Patient X has declined ERT at present, whilst patient Z is receiving therapy 
and patient Y has declined further assessment or management.  
 
Discussion 
 
Delays and difficulties in reaching a diagnosis of Fabry disease, recently described as the 
‘new great imposter’, are common4. Patient X required 35 years before diagnosis and his 
discordant siblings 7 years. This study highlights the value of revisiting historical 
diagnoses and the importance of family history in assessment, including organ disease 
other than that of the specialist area concerned. 
 
Our study also describes discordant phenotypic variants of Fabry disease within 3 
siblings sharing an identical mutation, which has not previously been reported. This 
adds further complexity to this disorder and raises the obvious possibility of genetic or 
environmental factors that can modify the course of variant disease. The R301Q 
mutation localises to a mutation hotspot18 and having been previously identified in both 
cardiac7 and renal8 variants of Fabry disease, it seems congruous that this mutation 
could produce the phenotypes observed in this family, with perhaps modifier genes or 
environmental factors influencing disease manifestations. We are presently attempting 
to identify genetic factors involved in these discordant siblings. 
 
Pursuing a diagnosis of Fabry disease, and in particular characterising the underlying 
gene mutation in each family, should now be considered routine clinical practice, given 
the advent of ERT and other treatment options under development19. In vitro and pre-
clinical studies of non-enzyme replacement based treatments try to chemically enhance 
the stability of the mutant aberrantly folded protein, by reducing early-targeted 
degradation of the abnormal protein (“chaperone therapy”). As this form of the protein 
retains enzymatic activity, this is proposed to result in less accumulation of 
glycosphingolipids, lowering disease burden and hopefully slowing progression17. 
Clinical studies are awaited. 
 
Raising awareness of the variant forms of Fabry disease and the possibility of 
discordant familial disease is important, as despite the availability of effective 
treatments, it remains common for long delays between presentation and diagnosis5,20. 
Early initiation of ERT is essential for maximum benefit and delayed diagnosis can 
result in irreversible disease unresponsive to ERT. Delays in diagnosis can also result in 
trials of inappropriate and potentially harmful alternative treatments, such as beta-
interferon or systemic corticosteroids4. Guidance exists for how to investigate or when 
to consider a diagnosis of Fabry disease13,20 but, ultimately all general physicians should 
be aware of ‘The Great Imposter’4.  
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Figure Legends 
 
Figure 1. Serum alpha-galactosidase levels, Family structure and mutational 
analysis 
 
A. Confirmation of significant α-galactosidase deficiency, but not absence of enzyme 
activity, was confirmed using standard tests.  
 
B. The family pedigree is shown with affected brothers in shaded squares. Unaffected 
family members are shown in unshaded symbols. Female carriers are shown with a 
circle with a dot in the centre 
 
C. Sequencing of the GLA gene in all 3 affected males confirmed a hemizygous change in 
the GLA gene, leading to a missense variant Arginine to Glutamine at amino acid 
position 301. Female carriers are heterozygous for this variant (data not shown). 
 
Table 1. Siblings sharing R301Q mutation have discordant phenotypic disease 
Clinical assessment and characteristics of siblings X, Y and Z compared to systems 
affected in classical Fabry disease (RRT renal replacement therapy). 
 
Figure 2. Retrospective analysis of native nephrectomy specimens for Sibling X 
 
A. The native renal biopsy specimen  (performed in 1984 for severe resistant 
hypertension) from patient X was reviewed and revealed no obvious features on H&E 
stained sections.  
 
B. Electron microscopy revealed a myelin figure suggestive of Fabry disease. 
 
Figure 3. Variant cardiac disease demonstrated by MRI imaging 
 
A. Typical delayed hyper-enhancement in posterior basal myocardium from post 
gadolinium enhancement images 
 
B. CINE derived end diastolic images demonstrating generalised left ventricular 
hypertrophy with more severe cardiac disease in siblings Y & Z, despite younger age 
and shorter duration of hypertension. 
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